Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Aims For Global Analgesic Market Dominance With Aleve, Aspirin

This article was originally published in The Tan Sheet

Executive Summary

The consolidation of the Aleve (naproxen sodium) franchise under one roof - and its pairing with Bayer Aspirin - appears to be a primary driver of Bayer's acquisition of Roche Consumer Health
Advertisement

Related Content

Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
Bayer/Roche Consumer Unit Will Focus On Rx-To-OTC Switch Opportunities
Bayer/Roche Consumer Unit Will Focus On Rx-To-OTC Switch Opportunities
Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
Bayer/Roche Consumer Unit Will Focus On Rx-To-OTC Switch Opportunities
Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
Bayer/Roche Consumer Unit Will Focus On Rx-To-OTC Switch Opportunities

Topics

Advertisement
UsernamePublicRestriction

Register

PS097081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel